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Objectives.T oc o m p a r et h ee ﬀectiveness of postcesarean thromboprophylaxis with two diﬀerent regimens of bemiparin. Material
and Methods. The study included 646 women with cesarean delivery in our hospital within a 1-year period, randomly assigned
to one of two groups for prophylaxis with 3500IU bemiparin once daily for 5 days or 3500IU bemiparin once daily for 10
days. Results. There was one case of pulmonary embolism (ﬁrst day following cesarean). An additional risk factor was present in
98.52% of the women, most frequently emergency cesarean, anemia, or obesity. The only risk factors for thromboembolic disease
signiﬁcantly related to pulmonary thromboembolism were placental abruption and prematurity. There were no diﬀerences in
thromboemboliceventsamongthetwothromboprophylaxisregimens.Conclusions.Cesarean-relatedthromboemboliceventswere
reduced in our study population due to the thromboprophylactic measures taken. Thromboprophylaxis with 3500IU bemiparin
once daily for 5 days following cesarean was suﬃcient to avoid thromboembolic events.
1.Introduction
Venous thromboembolism (VTE) remains one of the main
direct causes of maternal mortality in developed countries
[1–4], largely due to pulmonary thromboembolism (PE)
[5–7] which is responsible for around 20% of maternal
deaths [8]. Epidemiologic studies estimate the annual fre-
quency of deep venous thrombosis (DVT) in the general
population to be from 0.16‰[7]t o1 ‰ [ 9], of which 2% are
pregnancy related [5]. There is an increased risk of throm-
boembolic event, either DVT or PE, during pregnancy and
puerperium [5, 10], and it has been estimated that the risk of
VTE is 10-fold higher [11–15], reaching up to 2‰[16].
Puerperium is the period with highest VTE risk [12–14,
17, 18] which was reported to be up to 25-fold higher than
that in nonpregnant women [12–14]. It has been reported
that 43–60% of pregnancy-related PE episodes take place
during puerperium [11, 13].
The incidence of pregnancy-related VTE is estimated at
0.76 to 1.72‰[11, 18].
The incidence is likely to be underestimated, since wom-
en are often asymptomatic [19] or present nonspeciﬁc signs
or symptoms [20], and VTE during puerperium is often di-
agnosed or treated in a diﬀerent hospital from where the de-
livery took place [20, 21].
The incidence of puerperium-related VTE is 0.65‰[11].
Established risk factors for VTE during pregnancy in-
clude [9, 22] maternal age (1/800 for age >35 years; 1/1600
for age <35 years) [12, 13, 18, 23], obesity (body mass index
(BMI) >30) [24, 25], preeclampsia/hypertension, parity ≥3
[16], previous VTE or congenital or acquired thrombophilia
[17, 19, 20, 23, 26], smoking, diabetes [4], multiple gestation
[25], black race [27], and anaemia. During the labour there
are other factors [9]: type of delivery (with 3–6-fold higher
riskforcesareanversusvaginaldelivery,higherforemergency
cesarean [13, 28, 29], and mid-cavity instrumental delivery)2 Obstetrics and Gynecology International
[28, 29], prolonged labour >12 hours [10, 25, 28], immobili-
ty; major abdominal surgery for >30 minutes during preg-
nancy or puerperium [12], preterm delivery [11], excessive
bloodloss(>1litre),orbloodtransfusion.Inthepostpartum
period, other factorsmay be added as dehydration, immobil-
ity, and anaemia [9, 22].
The factors that contribute the most to the incidence of
thromboembolic events, due to their high prevalence, are
age >35 years, obesity, and cesarean delivery [28].
Cesarean delivery increases the risk of VTE because it
involves pelvic surgery that may last >30 minutes, adding to
the prothrombotic eﬀects of delivery, pregnancy weight gain,
and other risk factors (see above).
The VTE incidence rate following caesarean section is
1.78‰[11], with an odds ratio of 2 [11].
The latest guidelines [9, 16, 22] recommend that throm-
boprophylaxis with low-molecular-weight heparin (LMWH)
in women who undergo an emergency cesarean and in wom-
en who undergo an elective cesarean also has an additional
risk factor.
However, the duration of postcesarean thromboprophy-
laxis has been discussed and is an important factor, given the
elevated risk of VTE during puerperium, especially during
the ﬁrst week postpartum [9, 22] and the trend to earlier
postcesarean hospital discharge. So the latest guidelines [9]
recommend thromboprophylaxis in these women during
seven days.
However, there is no scientiﬁc evidence about the dura-
tion of the thromboprophylaxis, only clinical recommenda-
tions [7, 9, 22].
We investigated the incidence of VTE in women after
cesareansection(whohadnotrequiredLMWHduringpreg-
nancy) who received two diﬀerent LMWH regimens in order
to determine the best one to prevent this disease.
In our hospital, pneumatic compression is not used
as a method of thromboprophylaxis. After using diﬀerent
LMWH (enoxaparin, nadroparina, ...)a sp h a r m a c o l o g i c a l
thromboprophylaxis, the hospital ﬁnally established a policy
with bemiparin as postoperative thromboprophylaxis (gas-
trointestinal, thoracic, gynaecological, obstetrics, urological,
orthopedic surgery, ...) several years ago.
The safety and eﬃcacy of the LMWH bemiparin have
been demonstrated for the treatment and prophylaxis of ve-
nous thromboembolism. Bemiparin is a second-generation
LMWH. It is a sodium salt obtained by depolymerization of
nonfractioned heparin derived from pig intestinal mucosa.
Bemiparin has the lowest molecular weight (3600Da), the
longest half-life (5.3h), and the highest anti-FXa/anti-FIIa
activity ratio (8:1) of any second-generation LMWH [30].
The main objective was to compare the eﬀectiveness of
postcesarean thromboprophylaxis with two diﬀerent regi-
mensofbemiparin:3500IUoncedailyduringﬁvedaysversus
ten days.
2.MaterialandMethods
This research wasapproved by the ResearchEthical Commit-
tee of our university hospital.
2.1. Study. Comparison between ﬁve-day and ten-day bemi-
parin regimens (3500IU once daily) as postcesarean throm-
boprophylaxis.
Inclusion criteria for this study were women with a
cesarean delivery who had not required prophylaxis or treat-
ment with any type of LMWH during pregnancy (low risk
of VTE during pregnancy) and absence of allergy to heparin
or derivatives. Later, those women who did not fulﬁll the du-
ration of proposed prevention were excluded.
Outcome variables were the number of DVT and PE epi-
sodes and VTE-related maternal death up to 3 months fol-
lowingcesarean.Variablesassessedaspossibleriskfactorsfor
a thromboembolic event were age, smoking, obesity (BMI >
30), hypertension, parity, multiple pregnancy, diabetes, week
of delivery, type of cesarean (emergency or elective), type of
anesthesia, blood loss, and immobility (at least three days).
During the period of study, in our hospital 2924 deliver-
ies were attended; 742 cesarean were realized. All VTE cases
were registered.
96 women who underwent a cesarean section were ex-
cluded because they did not fulﬁll the inclusion criteria.
The study included 646 women with cesarean delivery in
our hospital during a 1-year period, assigned in a randomly
systematic way to one of two groups for prophylaxis with
3500IU bemiparin once daily for 5 days or 3500IU bemi-
parin once daily for 10 days.
Bemiparin was administered at least 8 hours following
cesarean. In case of locoregional anesthesia, Bemiparin was
not given until 8 hours after removing the epidural catheter.
Ac o m p l e t eb l o o dc o u n tt e s tw a sd o n et oa l lw o m e nw h o
underwent a cesarean within the next 24–36 hours.
We have chosen 5 and 10 days of thromboprophylaxis,
because5daysisrecommendedbytheclinicalpracticeguide-
lines before 2008, and we have chosen the comparison with
10 days, because the diﬀerent clotting factors begin to nor-
malize after the ﬁrst week postpartum, although the risk may
persist until the sixth week postpartum.
2.2. Statistical Analysis. Descriptive statistics were calculated
for all study variables. The chi-square test was used to com-
pare between 5-day and 10-day bemiparin.
A logistic regression model was used to analyze the dem-
ographic and morphometric variables and likelihood of
DVT/PE (dependent variables) with each regimen.
3. Results and Discussion
3.1. Results. During this period of time, 646 women with
cesarean delivery met the study inclusion criteria. Table 1
shows the characteristics of the women and their possible
thromboembolic risk factors during their pregnancy.
Mean age was 31 ± 5.47 years, 59.7% were nulliparous,
9% had ≥2 previous deliveries, and 14% were smokers. BMI
indicated that 42.3% of patients in the bemiparin groups
were obese (BMI > 30). Other possible risk factors for VTE
were diabetes (0.8–4.82%), hypertension during pregnancyObstetrics and Gynecology International 3
Table 1: Characteristics of patients in the study groups and predelivery thrombosis risk factors.
Thromboprophylactic Group A Group B
regimen Bemiparin 3500IU/5 days Bemiparin 3500IU/10 days
Number of cases (n) 311 335
Mean age ± SD 31.37 ± 5.24 31.06 ± 5.62
Age ≥35 years (n) (%) 89 (28.61%) 98 (29.25%)
Parity (n)( % )
0 149 (47.9%) 174 (51.9%)
1 90 (28.9%) 101 (30.1%)
2 46 (14.8%) 41 (12.2%)
3 13 (4.2%) 13 (3.9%)
≥4 13 (4.2%) 6 (1.8%)
BMI (n)( % )
BMI > 30 142 (45.8%) 116 (34.62%)
BMI > 35 36 (11.6%) 22 (6.56%)
Smoking (n) (%) 51 (16.5%) 40 (11.9%)
>10 cigs./day 16 (16%) 9 (2.25%)
Drug consumption (n) (%) 1 (0.3%) 1 (0.3%)
Multiple pregnancy (n) (%) 13 (4.2%) 19 (5.6%)
Hypertension (n)( % )
Chronic hypertension 6 (1.9%) 0
PIH in previous pregnancy 4 (1.3%) 6 (1.8%)
PIH in current pregnancy 34 (10.9%) 35 (10.4%)
Diabetes (n) (%) 15 (4.82%) 26 (1.8%)
Type I 3 (1%) 2 (0.6%)
Gestational diabetes 8 (2.6%) 18 (5.4%)
Carbohydrate intolerance 4 (1.3%) 6 (1.8%)
Previous heart disease (n) (%) 0 1 (0.3%)
Immobility (n) (%) 0 1 (0.3%)
BMI: body mass index, PIH: pregnancy-induced hypertension.
(10.7%), and multiple pregnancy (≈5%). There was a negli-
gible incidence of prolonged immobility, drug consumption,
or heart disease in our study population.
Table 2 shows the characteristics of the deliveries and the
associated thromboembolism risk factors. Cesareans were
almostalwaysatterm,withonly12.7%preterm,while73.6%
were emergency cesareans, an added thrombosis risk factor.
The most frequent anesthesia was locoregional (88.3%).
Other potential thrombosis factors (due to the possible un-
derlying disease) were placental abruption (2.2%) and intra-
uterine growth retardation (IUGR) (8.5%). In the present
study,onlyplacentalabruptionandgestationalage(preterm)
were signiﬁcantly related to PE (P<0.005).
Table 3 depicts the thrombosis risk factors recorded after
the cesarean. Anemia (Hb < 11) was the most prevalent risk
factor(75.4%womenaftercesareansection),followedbyhy-
pertension (4.9%) and infection (6.4%). Almost all women
(98.53%) had an additional risk factor beside the cesarean.
There were neither maternal deaths nor any DVT cases.
There was only one PE case. This case was in a 25-year-
old nulliparous woman assigned to group B with a BMI of
29.5 and no family history of thrombosis; her smoking habit
of <10 cigarettes/day was the only risk factor during preg-
nancy. She was hospitalized in week 32 with placental
abruption symptoms and underwent emergency cesarean
with locoregional anesthesia. At this time two other risk
factors were added up: emergency cesarean section and
vaginal bleeding. The fetus was delivered alive with appro-
priate weight for gestational age. The mother presented with
moderate anemia that required intravenous iron treat-
ment. On the ﬁrst postoperative day, before beginning the
thrombophylaxis with bemiparin, she reported diﬃculty in
breathing and pain in right costodiaphragmatic recess. PE
was diagnosed after clinical examination, elevated D-dimer,
and complementary tests: perfusion lung scintigraphy (PE
in lateral and medial segments of medial lobe of right lung)
and bilateral lower limb Doppler’s ultrasound examination
(normal). Consequently, a therapeutic LMWH regimen was
started instead of the thromboprophylaxis regimen and was
subsequently replaced with oral anticoagulant therapy. A
hypercoagulation test at 6 months ruled out thrombophilias.
Hence, the incidence of VTE in this series (women with
cesarean delivery) was 1,54% and the incidence of VTE in
total number of deliveries was 0,34% (1/2924).4 Obstetrics and Gynecology International
Table 2: Characteristics of the surgery by study group and thrombosis risk factors during the cesarean.
Thromboprophylactic Group A Group B
regimen Bemiparin 3500IU/5 days Bemiparin 3500IU/10 days
(number of cases) (n = 311) (n = 335)
Type of cesarean (n)( % )
Elective 82 (26.4%) 88 (26.4%)
Emergency 229 (73.6%) 247 (73.6%)
Type of anesthesia (n)( % )
Locoregional 278 (89.7%) 290 (86.6%)
General 31 (10.3%) 45 (13.77%)
Delivery GW (mean ± SD) 38.54 ±2.47 38.66 ±2.23
Preterm (n) (%) 40 (12.9%) 41 (12.4%)
Placental abruption (n) (%) 7 (2.3%) 7 (2.1%)
IUGR (n) (%) 24 (7.7%) 31 (9.3%)
IUGR: intrauterine growth retardation, GW: weeks of gestation.
Table 3: Postcesarean thrombosis risk factors.
Thromboprophylactic regimen Group A Group B
(number of cases) Bemiparin 3500IU/5 days Bemiparin 3500IU/10 days
(n = 311) (n = 335)
Postcesarean anemia (n)( % )
Hb < 11 222 (71.38%) 249 (74.32%)
Hb < 10 161 (51.8%) 179 (53.5%)
Hb ≤ 9 72 (23.4%) 89 (26.6%)
Infection 21 (6.8%) 20 (6%)
Seroma 17 (5.5%) 16 (4.8%)
Postcesarean hypertension 15 (5.7%) 9 (4%)
Hb: hemoglobin.
Considering that the only PE case occurred on the ﬁrst
postoperative day, before beginning the thromboprophylax-
is, comparisons among the diﬀerent LMWH regimens were
not appropriate.
3.2. Discussion. There is a continual and exhaustive surveil-
lance of VTE risk factors during pregnancy and puerperium
at our hospital, and appropriate thromboprophylactic mea-
sures are implemented when they are detected [31].
Those measures are recommendations of exercises for
earlymobilizationforfootandlegs,earlyambulation(within
two hours after the vaginal delivery and 6–8 hours after cesa-
rean section), women are well hydrated with serum therapy
in puerperium, and liquid and food are administered early
(immediately after vaginal delivery; at 4–6 hours after cesa-
rean section with locoregional anesthesia and 6–8 hours
after cesarean section with general anesthesia) and LMWH
thromboprophylaxis starts at least 8 hours following cesa-
rean.
This policy may explain why only one episode of VTE
was observed in the hospital during the period studied; this
case took place during the ﬁrst 24 hours after cesarean for
placental abruption.
Given the total number of deliveries at the hospital
(2924)duringthisperiod,anincidencefrom2to5VTEcases
related to pregnancy, delivery, and puerperium could be ex-
pected [10, 11, 28].
The fact that only one case was observed may suggest a
lowerpresenceofriskfactorsinourpopulation;nevertheless,
98.53% of studied women had at least one other thrombosis
risk factor besides the cesarean surgery.
When we analyzed the risk factors, compared with that
reported in other studies, we observed that, although women
inourstudyha v eriskfact orsforVTE(ageo v er35y ears30%,
obesity 30%, emergency cesarean section >70%, anaemia
50%). We only had one case of VTE (risk factors presented:
smoking, emergency cesarean section, preterm delivery,
vaginal bleeding, and severe anemia).
The most frequent risk factors in our population were
emergency cesarean, anaemia, and obesity. Special attention
is given to VTE prevention at our center, and all women are
closely followed up for risk factors throughout their preg-
nancy and puerperium to determine any need for thrombo-
prophylaxis.
In our hospital, the thromboprophylaxis measures may
helptoexplainourﬁndingofalower-incidenceVTE(0,34%)
than that of in published reports [11, 32]. Regional anes-
thesia (epidural/dural) was used in more than 90%, cases of
caesarean section, and this fact can reduce the risk of VTE
[24].Obstetrics and Gynecology International 5
Historically in our hospital, LMWH was prescribed in all
cases of cesarean delivery; since the early postcesarean hos-
pital discharge policy (third day following cesarean) began,
we reconsidered whether to continue the prophylaxis after
the hospital discharge or not.
Some authors have recommended the postcesarean use
of LMWH only when there is an additional risk factor or in
cases of emergency cesarean [29]. However, we agree with
the recommendations of several clinical practice guidelines
[9, 22], which have recommended that the threshold for
prescribing thromboprophylaxis should be lower in the
postnatal period than that in the antenatal period since the
risk of developing VTE per day is higher and the duration
of exposure shorter. Even some of them [9] recommend that
all women, who have had an emergency caesarean section or
an elective cesarean section and have one or more additional
riskfactorsforVTE,shouldreceivethromboprophylaxiswith
LMWH for seven days.
We prescribe LMWH in all cesareans, both elective
and emergency, because we cannot know ap r i o r iwhether
another thrombosis risk factor will appear in puerperium
(e.g., anaemia, infection, hypertension) or whether a longer
rest period will be required (e.g., for postpuncture headache,
infection). In fact, 98.53% of the present series of women
with cesarean had at least one more risk factor.
At our hospital, the high rate of VTE risk factors may be
duetothecontinualandexhaustivesurveillanceoftheseVTE
risk factors, included period puerperium; so you might be
able to detect more risk factors than other hospitals. In our
department, a blood test is performed within 24–36 hours
after a cesarean section to count red blood cells, leukocytes,
and platelets, which detects anaemia that otherwise may go
unnoticed.
In our view, the beneﬁts of postcesarean LMWH admin-
istration in minimizing the risk of thromboembolic events
greatly outweigh the low level of risk associated with its use
[33, 34].
I no u rs t u d y ,w eh a v en o th a da n ya d v e r s ee ﬀects from
the administration of LMWH (bleeding, thrombocytopenia
induced by LMWH).
We agree with the recommendations of recent clinical
practice guidelines [16]; and although, a cost-eﬀectiveness
analysis was not completed speciﬁcally for this population
subgroup, the cost-eﬀectiveness model for medical patients
indicates that prophylaxis with LMWH is cost eﬀective for
patients at increased risk. In our investigation, bemiparin
3500oncedailyduringﬁvedayshasbeensuﬃcienttoprevent
thromboembolic events, so health costs are lower (two days
less than recommended in the clinical practice guideline)
[9], although clotting factors may take a few more days to
normalize.
4. Conclusions
A reduction in the incidence of thromboembolic disease
can be achieved by surveillance of risk factors during the
pregnancy,delivery,andpuerperiumalongsidephysicalmea-
sures and thromboprophylaxis with low-molecular-weight
heparin.
In case of women with cesarean delivery, we recommend
adding thromboprophylaxis with low-molecular-weight he-
parin (like Bemiparin) during ﬁve days following cesarean.
These actions seem to be adequate to avoid thromboem-
bolic events, although the continuation of thromboprophy-
laxis should be considered if other risk factors emerge.
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